GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » 3-Year Dividend Growth Rate

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) 3-Year Dividend Growth Rate : -7.20% (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co 3-Year Dividend Growth Rate?

Chugai Pharmaceutical Co's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The historical rank and industry rank for Chugai Pharmaceutical Co's 3-Year Dividend Growth Rate or its related term are showing as below:

CHGCF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -7.2   Med: 10.1   Max: 69.1
Current: -7.2

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Chugai Pharmaceutical Co was 69.10% per year. The lowest was -7.20% per year. And the median was 10.10% per year.

CHGCF's 3-Year Dividend Growth Rate is ranked worse than
76.4% of 322 companies
in the Drug Manufacturers industry
Industry Median: 9.1 vs CHGCF: -7.20

During the past 12 months, Chugai Pharmaceutical Co's average Dividends Per Share Growth Rate was 2.60% per year. During the past 3 years, the average Dividends Per Share Growth Rate was -7.20% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 27.20% per year. During the past 10 years, the average Dividends Per Share Growth Rate was 23.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Chugai Pharmaceutical Co's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Chugai Pharmaceutical Co's Dividend Yield % is 1.66%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Chugai Pharmaceutical Co's 3-Year Dividend Growth Rate

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co's 3-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's 3-Year Dividend Growth Rate falls into.



Chugai Pharmaceutical Co 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Chugai Pharmaceutical Co  (OTCPK:CHGCF) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Chugai Pharmaceutical Co's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2024 )/ EPS without NRI (Q: Mar. 2024 )
=0/ 0.302
=0.00

During the past 13 years, the highest Dividend Payout Ratio of Chugai Pharmaceutical Co was 0.75. The lowest was 0.31. And the median was 0.43.

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Chugai Pharmaceutical Co Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
JPY 40.0002023-12-282023-12-312024-03-29Cash Dividendsemi-annuallyJPY:USD 0.007091
JPY 40.0002023-06-292023-06-302023-08-30Cash Dividendsemi-annuallyJPY:USD 0.006922

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Chugai Pharmaceutical Co's Dividend Yield (%) for Today is calculated as

Dividend Yield %=Most Recent Full Year Dividend/Current Share Price
=0.56052/32.43
=1.73 %

Current Share Price is $32.43.
Chugai Pharmaceutical Co's Dividends per Share for the trailing twelve months (TTM) ended in Today is $0.56052.

During the past 13 years, the highest Dividend Yield of Chugai Pharmaceutical Co was 2.51%. The lowest was 0.55%. And the median was 1.42%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chugai Pharmaceutical Co 3-Year Dividend Growth Rate Related Terms>


Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines